Skip to content

Cardiopediatric Home Monitoring Tool

Cardiopediatric Home Monitoring Tool

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06741189
Acronym
OSCAR
Enrollment
186
Registered
2024-12-18
Start date
2025-10-30
Completion date
2028-07-30
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Defect

Keywords

Congenital heart defects, cardiac surgery, care pathway, home monitoring, morbidity and mortality

Brief summary

We hypothesize that a home monitoring program combined with routine postoperative care significantly reduces morbidity and mortality after neonatal and pediatric cardiac surgery. This project differs from the previously published experiences by (a) providing an innovative telemedicine solution via the use of validated measurement sensors, (b) an alert system based on individualized standards, established for each care pathway, and (c) a protocolized response from medical teams in the management of alerts generated by the home monitoring tool.

Detailed description

Affecting 12-million people worldwide and 7,400 newborns/year in France, congenital heart defects (CHD) are the leading cause of birth defects and a major cause of morbidity and mortality in childhood. It is (a) a growing patient population, due to an increase in birth prevalence and survival, and (b) a major public health issue, due to a substantial use of healthcare resources and a dramatic impact on quality of life. CHDs concerned by the OSCAR project are rare diseases (prevalence \<1/2000 births) operated on at birth or in infancy. These CHDs expose affected newborns/infants to the risk of major cardiovascular events (fainting, cyanosis, arrhythmias) and/or rapid cardiac decompensation occurring at home in the postoperative period, justifying close ambulatory monitoring to detect early warning signs of complication or decompensation (such as oxygen desaturation, accelerated heart rate, poor weight gain, altered tone, etc.) This risk is particularly high in certain critical postoperative situations, such as when the physiology of a single ventricle is palliated by a shunt (modified Blalock-Taussig systemic-pulmonary anatomy), or in the intermediate period (interstage) between two palliative surgeries in a Norwood program. In view of the high ambulatory mortality (12-20% in current series) during the interstage of a Norwood program, some expert centers around the world have opted not to discharge operated neonates home, preferring to keep in-hospital monitoring during 4 to 5 months, until stage 2, thus reducing mortality during this critical period. In Anglo-Saxon countries, an outpatient monitoring program has been developed as an alternative for these vulnerable patients, sometimes accompanied by a telemedicine solution, greatly reducing postoperative mortality. This type of outpatient follow-up program does not exist in France.

Interventions

The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child. An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home. The response will be standardized on the basis of a protocol shared by the 4 investigating centers.

OTHERusual medical monitoring

During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram. During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures.

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 36 Months
Healthy volunteers
No

Inclusion criteria

* Patients aged between 0 and 36 months inclusive * With a congenital heart defect * Underwent cardiac surgery at Nantes University Hospital * Affiliated to a social security scheme * Free, informed and written consent of the 2 holders of parental authority Non Inclusion Criteria: * Clinical or family situation contraindicating a return home * Physical inability to connect to the Exolis platform at home * Insufficient understanding on the part of those with parental authority * Extracardiac co-morbidities responsible for organ failure requiring repeated * Hospitalisation for non-cardiovascular reasons (e.g. severe renal failure, neurological neurological deficit, complex immune deficiency, etc). * Patient and/or parents under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Reducing postoperative morbidity and mortality6th month post-opThe main objective is to evaluate the impact of home monitoring in reducing postoperative morbidity and mortality in patients aged 0 to 36 months who have undergone MCC.

Secondary

MeasureTime frameDescription
Children's quality of life0,1 month, 3 months and 6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: Children's quality of life during the postoperative period.
Parents' quality of life0,1 month, 3 months and 6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: Parents' quality of life during the postoperative period
Parental stress0,1 month, 3 months and 6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: Parental stress and family impact during the postoperative period
Children's weight growth1 month, 3 months and 6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: Children's weight growth during the postoperative period
Post-traumatic stress syndromes6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: The prevalence of post-traumatic stress syndromes in parents at the postoperative month.
Serious non-cardiovascular events6 months post opAssess the impact of OSCAR surveillance by comparing the 2 groups: The rate of serious non-cardiovascular events (in order to study a potential delay in the management of these events in the group with OSCAR monitoring group due to increased follow-up).
Factors other than management6 months post opTo study the impact of factors other than management (OSCAR monitoring versus management) on the parents' quality of life, parental stress and family impact family impact, children's weight gain, and the presence of post-traumatic stress post-traumatic stress disorder in the parents 6 months after the operation.
Therapeutic education program6 months post opEvaluate the conditions for implementing OSCAR surveillance by assessing : The relevance of the OSCAR therapeutic education program (ETP) for the parents in the group concerned.
Acceptability of monitoring for the parents6 months post opEvaluate the conditions for implementing OSCAR surveillance by assessing : The acceptability of monitoring for the parents in the group concerned.
Acceptability of the monitoring for the medical teams6 months post opEvaluate the conditions for implementing OSCAR surveillance by assessing : The acceptability of the monitoring for the medical teams (investigating hospital investigating hospital medical teams and the child's routine care medical teams).
Efficiency6 months post opEvaluate the conditions for implementing OSCAR surveillance by assessing : its efficiency.

Countries

France

Contacts

CONTACTAlban-Elouen Baruteau, Pr
albanelouen.baruteau@chu-nantes.fr+33

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026